Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FYN | P06241 | 13/20 | 0.49 |
| ▸ | CDK8 | P49336 | 1/20 | 0.47 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.44 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.44 |
| ▸ | PRKCI | P41743 | 1/20 | 0.44 |
| ▸ | HSD17B1 | P14061 | 2/20 | 0.44 |
| ▸ | HSD17B2 | P37059 | 2/20 | 0.44 |
| ▸ | ATR | Q13535 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29462100 | 1.00 | FYN (0.49) | FYNCDK8CHEK1CHEK2PRKCI | |
| SCHEMBL16675787 | 0.87 | FYN (0.51) | FYNCDK8CHEK1CHEK2PRKCI | |
| SCHEMBL16675771 | 0.81 | HSD17B1 (0.64) | FYNCDK8PRKCIHSD17B1HSD17B2 | |
| SCHEMBL29914764 | 0.80 | HSD17B1 (0.71) | FYNHSD17B1HSD17B2 | |
| SCHEMBL21228179 | 0.80 | HSD17B1 (0.71) | FYNHSD17B1HSD17B2 | |
| SCHEMBL12241214 | 0.80 | CDK8 (0.50) | FYNCDK8CHEK1CHEK2PRKCI | |
| SCHEMBL16675774 | 0.79 | FYN (0.58) | FYNCHEK1CHEK2PRKCI | |
| SCHEMBL16675760 | 0.79 | CNR1 (0.48) | FYNCDK8PRKCI | |
| SCHEMBL23601693 | 0.78 | KDR (0.48) | HSD17B1HSD17B2ATR | |
| SCHEMBL23309287 | 0.78 | CYP4F2 (0.48) | FYNCDK8CHEK1CHEK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110218218-B | Benzofuran derivative, preparation method and medical application thereof | 江苏恒瑞医药股份有限公司 | 2022-04-08 | — | — | CN | disclosed |
| EP-2855489-B1 | IMIDAZOTHIADIAZOLE AND IMIDAZOPYRIDAZINE DERIVATIVES AS PROTEASE ACTIVATED RECEPTOR 4 (PAR4) INHIBITORS FOR TREATING PLATELET AGGREGATION | BRISTOL MYERS SQUIBB CO (US) | 2017-01-04 | — | — | EP | disclosed |
| US-9518064-B2 | Imidazothiadiazole and imidazopyridazine derivatives as protease activated receptor 4 (PAR4) inhibitors for treating platelet aggregation | BRISTOL-MYERS SQUIBB COMPANY (US) | 2016-12-13 | — | — | US | disclosed |
| US-9518064-B2 | Imidazothiadiazole and imidazopyridazine derivatives as protease activated receptor 4 (PAR4) inhibitors for treating platelet aggregation | BRISTOL-MYERS SQUIBB COMPANY (US) | 2016-12-13 | — | — | US | disclosed |
| US-20150119390-A1 | IMIDAZOTHIADIAZOLE AND IMIDAZOPYRIDAZINE DERIVATIVES AS PROTEASE ACTIVATED RECEPTOR 4 (PAR4) INHIBITORS FOR TREATING PLATELET AGGREGATION | BRISTOL-MYERS SQUIBB COMPANY | 2015-04-30 | — | — | US | disclosed |
| US-20150119390-A1 | IMIDAZOTHIADIAZOLE AND IMIDAZOPYRIDAZINE DERIVATIVES AS PROTEASE ACTIVATED RECEPTOR 4 (PAR4) INHIBITORS FOR TREATING PLATELET AGGREGATION | BRISTOL-MYERS SQUIBB COMPANY | 2015-04-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150119390-A1 | IMIDAZOTHIADIAZOLE AND IMIDAZOPYRIDAZINE DERIVATIVES AS PROTEASE ACTIVATED RECEPTOR 4 (PAR4) INHIBITORS FOR TREATING PLATELET AGGREGATION | F2RL3, F2R, F2RL1 | FYN 1063/4885CDK8 605/4885CHEK1 3366/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.